01 1Nebulized Tyvaso
02 5Remodulin
03 4Tyvaso
04 1Tyvaso DPI
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 587
2018 Revenue in Millions : 599
Growth (%) : -2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 416
2018 Revenue in Millions : 415
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 517
2019 Revenue in Millions : 587
Growth (%) : -12
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 483
2019 Revenue in Millions : 416
Growth (%) : 16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 608
2020 Revenue in Millions : 483
Growth (%) : 26
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 514
2020 Revenue in Millions : 517
Growth (%) : -1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 500
2021 Revenue in Millions : 514
Growth (%) : -3
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 873
2021 Revenue in Millions : 608
Growth (%) : 44
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 495
2022 Revenue in Millions : 500
Growth (%) : -1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 731
2022 Revenue in Millions : 158
Growth (%) : 362
LOOKING FOR A SUPPLIER?